Not All COVID Patients Benefit From JAK Inhibitor

Source link :

People randomized to the Janus kinase (JAK) inhibitor baricitinib (Olumiant) to treat COVID-19 pneumonia in a clinical trial only saw a survival benefit if they had obesity, a post-hoc analysis found. Death within 28 days of starting treatment occurred in 5.6% of patients with body mass index (BMI) values >30, compared with 9.2% of those […]

Author : News Health

Publish date : 2024-05-28 16:02:55

Copyright for syndicated content belongs to the linked Source.